Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
2019 · Clinical Cancer Research · 107 citations
https://doi.org/10.1158/1078-0432.ccr-19-0475
X
Xiaowen Wu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
134
Papers
3.5K
Citations
26
h-index
49
i10-index
Xiaowen Wu is an academic researcher from Peking University. The author has contributed to research in topics: Cutaneous Melanoma Detection and Management & Melanoma and MAPK Pathways & Cancer Immunotherapy and Biomarkers. The author has an h-index of 26, co-authored 114 publications.
ORCID: 0000-0002-3728-2684Papers by this author
worksLncRNA UCA1 facilitated cell growth and invasion through the miR-206/CLOCK axis in glioma
2019 · Cancer Cell International · 30 citations
https://doi.org/10.1186/s12935-019-1023-7
HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population
2023 · The Oncologist · 26 citations
https://doi.org/10.1093/oncolo/oyad070
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma
2023 · JAMA Oncology · 26 citations
https://doi.org/10.1001/jamaoncol.2023.1363
Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial
2023 · European Journal of Cancer · 25 citations
https://doi.org/10.1016/j.ejca.2022.12.027
FMRP ligand circZNF609 destabilizes RAC1 mRNA to reduce metastasis in acral melanoma and cutaneous melanoma
2022 · Journal of Experimental & Clinical Cancer Research · 20 citations
https://doi.org/10.1186/s13046-022-02357-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat